Citeline Podcasts

On this week's podcast, David Filmore and Tina Tan discussed the MTI 100, our annual analysis of revenue leaders in the medtech space.

Office of New Drug Director John Jenkins, who will be leaving FDA on January 6, reflects on his 25-year tenure at the agency. Topics include the innate variability between FDA review divisions, his future plans and the one regulatory decision he would change, if he could turn back time.

Office of New Drug Director John Jenkins, who will be leaving FDA on January 6, reflects on his 25-year tenure at the agency. Topics include the innate variability between FDA review divisions, his future plans and the one regulatory decision he would change, if he could turn back time.

Office of New Drug Director John Jenkins, who will be leaving FDA on January 6, reflects on his 25-year tenure at the agency. Topics include the innate variability between FDA review divisions, his future plans and the one regulatory decision he would change, if he could turn back time.

Friends of Cancer Research CEO Jeff Allen sits down with Ramsey Baghdadi and discusses the passage of the 21st Century Cures Act, the implementation of the bill and FDA’s Oncology Center of Excellence, what could be added to PDUFA VI, working with the Trump Administration, and the ideal profile of the next FDA Commissioner.

Friends of Cancer Research CEO Jeff Allen sits down with Ramsey Baghdadi and discusses the passage of the 21st Century Cures Act, the implementation of the bill and FDA’s Oncology Center of Excellence, what could be added to PDUFA VI, working with the Trump Administration, and the ideal profile of the next FDA Commissioner.

Friends of Cancer Research CEO Jeff Allen sits down with Ramsey Baghdadi and discusses the passage of the 21st Century Cures Act, the implementation of the bill and FDA’s Oncology Center of Excellence, what could be added to PDUFA VI, working with the Trump Administration, and the ideal profile of the next FDA Commissioner.

On this week's podcast, Shawn Schmitt talks about his examination of gaps by FDA investigators in the use of the Quality System Inspection Technique, Ferdous Al-Faruque discusses his deep-dive into medtech efforts in cybersecurity protection, and Sue Darcey and Elizabeth Orr provide updates from the Hill and FDA. Also, the latest name to float for FDA commissioner post in Trump Administration.

On this week's podcast, Shawn Schmitt talks about his examination of gaps by FDA investigators in the use of the Quality System Inspection Technique, Ferdous Al-Faruque discusses his deep-dive into medtech efforts in cybersecurity protection, and Sue Darcey and Elizabeth Orr provide updates from the Hill and FDA. Also, the latest name to float for FDA commissioner post in Trump Administration.

On this week's podcast, Shawn Schmitt talks about his examination of gaps by FDA investigators in the use of the Quality System Inspection Technique, Ferdous Al-Faruque discusses his deep-dive into medtech efforts in cybersecurity protection, and Sue Darcey and Elizabeth Orr provide updates from the Hill and FDA. Also, the latest name to float for FDA commissioner post in Trump Administration.